Serum Biomarkers Are Associated With Treatment Response in Relapsed Mantle Cell Lymphoma

Abstract

59% of patients) and poor risk (4 points, 17% of patients). Two-year OS rates were 81%, 47%, and 21%, respectively (p < 0.0001) (figure). Conclusion:This easy-to-compute scoring index may allow the identification of groups of transformed WM patients with different outcomes and could be used for improving treatment choices.